NextCure Inc Total Assets
NextCure Inc total assets. Based on the latest financial reports, NextCure Inc (NXTC) holds total assets worth $22.62 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NextCure Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of NextCure Inc (2017–2025)
Total assets of NextCure Inc from 2017 to 2025. This chart illustrates how NextCure Inc's total assets have evolved over time, based on quarterly financial data. See NXTC stock price for real-time trading data and today's change.
NextCure Inc - Asset Composition Analysis
NextCure Inc Total Assets Breakdown (December 2025)
NextCure Inc total assets breakdown as of December 2025. NextCure Inc's total assets of $22.62 Million consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.8% |
| Accounts Receivable | $100.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how NextCure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NXTC working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NextCure Inc's current assets represent 87.2% of total assets in 2025, an increase from 48.4% in 2017.
- Cash Position: Cash and equivalents constituted 51.8% of total assets in 2025, up from 43.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
NextCure Inc Competitors by Total Assets
Key competitors of NextCure Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
NextCure Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.47 | 3.71 | 32.95 |
| Quick Ratio | 3.47 | 3.71 | 32.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.84 Million | $29.23 Million | $235.66 Million |
NextCure Inc - Advanced Valuation Insights
This section examines the relationship between NextCure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | -37.9% |
| Total Assets | $50.18 Million |
| Market Capitalization | $27.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values NextCure Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NextCure Inc's assets decreased by 37.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NextCure Inc (2017–2025)
The table below shows the annual total assets of NextCure Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $50.18 Million | -37.94% |
| 2024-12-31 | $80.86 Million | -36.85% |
| 2023-12-31 | $128.04 Million | -30.47% |
| 2022-12-31 | $184.16 Million | -24.02% |
| 2021-12-31 | $242.39 Million | -20.96% |
| 2020-12-31 | $306.64 Million | -13.90% |
| 2019-12-31 | $356.17 Million | +141.26% |
| 2018-12-31 | $147.63 Million | +658.35% |
| 2017-12-31 | $19.47 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more